Augmentt and SeedPod Bring to Market Cyber Insurance Program for MSPs and their Customers
SeedPod Cyber Rewards channel partners using Augmentt Discover and Augmentt Secure to improve security posture…
SeedPod Cyber Rewards channel partners using Augmentt Discover and Augmentt Secure to improve security posture…
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating…
Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET NEW YORK, NY,…
— Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12…
Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall…
WARREN, N.J., June 06, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
— Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin —…
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — Xalud Therapeutics, a clinical-stage biotechnology company developing…
Judy Chou, Ph.D. President and CEO SAN FRANCISCO, June 06, 2022 (GLOBE NEWSWIRE) — AltruBio…
REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR), a…
Company expands its partnerships with leading patient advocacy groups to improve NASH education and patient…
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and…
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as…
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB),…
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures…
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with…
– Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase…
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive…
Trial will be the first clinical study of Allocetra™ in patients with cancer, following encouraging…